Inst. Holders
50 funds
APLS
Apellis Pharmaceuticals, Inc.
—
12-mo target$40.92 (-0.3%)
High Impact Filing (8/10)48 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on APLS right now — valuation, ownership and activity at a glance.
Inst. Value
$4.4B
Inst. Activity
0 buys / 48 sells
SEC Reports
5
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 21, 2026 Event
Empaveli
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA EMPAVELI, a complement inhibitor, increa
Jul 29, 2026 earnings_calendar
APLS Q2 2026 Earnings Scheduled — 2026-07-29
Jun 30, 2026 Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
May 26, 2026 SEC Magnetar Financial LLC — EXIT
0 shares ($0.00)
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting obligations, effective
15-12G — Impact 6/10
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May
25-NSE — Impact 2/10
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent merge
8-K — Impact 8/10
May 14, 2026 Insider
Watson David O. disposed of 11,874 shares
General Counsel
Analyst ratings buy % -55.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 16, 2024 | Scotiabank | INITIATE | Sector Perform | 56% |
| Oct 16, 2024 | William Blair | INITIATE | Outperform | 51% |
| Sep 24, 2024 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Sep 23, 2024 | Baird | MAINTAIN | Outperform | 54% |
| Sep 20, 2024 | Mizuho | MAINTAIN | Neutral | 52% |
| Sep 20, 2024 | Needham | REITERATE | Buy | 50% |
| Sep 13, 2024 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 13, 2024 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 9, 2024 | UBS | MAINTAIN | Buy | 55% |
| Aug 9, 2024 | Wedbush | MAINTAIN | Neutral | 57% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| Aug 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| Jul 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| Jun 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| May 1, 2026 | 3 | 5 | 19 | 0 | 0 | 30% | |
| Apr 1, 2026 | 3 | 9 | 15 | 0 | 0 | 44% | |
| Mar 1, 2026 | 8 | 12 | 8 | 1 | 0 | 69% | |
| Feb 1, 2026 | 8 | 12 | 7 | 1 | 0 | 71% |
Price targets
Where 13 covering analysts think APLS trades over the next 12 months.
$40.92 -0.3% upside Hold
Current$41.03 Low$40.00 Median$41.00 High$41.00 13 analysts
$40.00$41.00
Analyst rating Hold· 2.9/5 as of Jul 18, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 0 bearish, 1 mixed, 3 neutral · avg impact 4.8/10.
NEUTRAL15-12G6/10
Apellis Pharmaceuticals filed Form 15-12G to terminate its SEC registration and suspend reporting ob
May 26, 2026
NEUTRAL25-NSE2/10
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registra
May 14, 2026
BULLISH8-K8/10
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer
May 14, 2026
NEUTRAL8-K2/10
Apellis Pharmaceuticals amended its Executive Separation Benefits and Retention Plan in connection w
May 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 21, 2026
FDA
Empaveli
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA EMPAVELI, a complement inhibitor, increases the risk of serious infections, especially tho
Jul 29, 2026
earnings_calendar
APLS Q2 2026 Earnings Scheduled — 2026-07-29
Jun 18, 2026
Clinical Trial
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Phase Phase 3 — COMPLETED
Jun 5, 2026
Clinical Trial
Pegcetacoplan Long Term Safety and Efficacy Extension Study
Phase Phase 3 — COMPLETED
May 11, 2026
dark_pool
Dark Pool: APLS — 13.4M shares, 34,348 trades
Week starting 2026-05-11. Total ATS volume: 13,393,774 shares across 34,348 trades.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.32 | $-0.49–$-0.16 | 3.8% | +3.5% | 0↑ 2↓ | $0.2B | 8 |
| Next Q | $-0.28 | $-0.60–$-0.10 | -116.8% | -6.2% | 1↑ 1↓ | $0.2B | 8 |
| Next FY | $-0.31 | $-2.02–$0.68 | 73.2% | -28.7% | 3↑ 2↓ | $1.0B | 7 |
| Current FY | $-1.17 | $-2.19–$-0.38 | -686.9% | -4.1% | 2↑ 1↓ | $0.9B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.318 | — |
| 7d ago | $-0.329 | +0.012 |
| 30d ago | $-0.329 | +0.012 |
| 60d ago | $-0.309 | -0.008 |
| 90d ago | $-0.353 | +0.035 |
Institutional ownership
Which big funds own APLS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.4B total value (110,804,632 shares) as of 2026-Q1. Top holders: Clear, BlackRock,, Avoro. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Clear Street Group Inc. | 350,000 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 13,536,964 | $544.6M | 12.4% | EXIT -100.0% |
| Avoro Capital Advisors LLC | 12,222,222 | $491.7M | 11.2% | EXIT -100.0% |
| MORGAN STANLEY | 10,042,399 | $404.0M | 9.2% | EXIT -100.0% |
| STATE STREET CORP | 6,844,990 | $275.4M | 6.3% | EXIT -100.0% |
| UBS Group AG | 6,206,681 | $249.7M | 5.7% | EXIT -100.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,404,559 | $217.4M | 5.0% | EXIT -100.0% |
| Pentwater Capital Management LP | 5,250,000 | $211.2M | 4.8% | EXIT -100.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,768,944 | $191.9M | 4.4% | EXIT -100.0% |
| Point72 Asset Management, L.P. | 4,183,918 | $168.3M | 3.8% | EXIT -100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | EXIT | 6,844,990 | 0 | -100.0% | $0.00 |
| Magnetar Financial LLC | EXIT | 869,229 | 0 | -100.0% | $0.00 |
| Avoro Capital Advisors LLC | EXIT | 12,222,222 | 0 | -100.0% | $0.00 |
| RTW INVESTMENTS, LP | EXIT | 3,685,045 | 0 | -100.0% | $0.00 |
| Jump Financial, LLC | EXIT | 291,488 | 0 | -100.0% | $0.00 |
| GABELLI FUNDS LLC | EXIT | 321,200 | 0 | -100.0% | $0.00 |
| Pentwater Capital Management LP | EXIT | 5,250,000 | 0 | -100.0% | $0.00 |
| Verition Fund Management LLC | EXIT | 400,000 | 0 | -100.0% | $0.00 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | EXIT | 1,013,500 | 0 | -100.0% | $0.00 |
| LMR Partners LLP | EXIT | 403,622 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Watson David O. | General Counsel | D | 11,874 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 6,001 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 7,363 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 14,000 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 50,974 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 38,250 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 45,000 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 37,708 | — | — |
| May 14, 2026 | Watson David O. | General Counsel | D | 34,533 | — | — |
| May 14, 2026 | Francois Cedric | Chief Executive Officer | U | 372,815 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for APLS.
Shares short
10,752,810
Settlement Apr 30, 2026
Change vs prior
-24.5%
Semi-monthly cycle
Days to cover
3.1
At avg daily volume
All APLS filing & press-release reports (5)
- 15-12G reportMay 26, 2026
- 25-NSE reportMay 14, 2026
- 8-K reportMay 14, 2026
- 8-K reportMay 4, 2026
- INST-CLUSTER reportMar 27, 2026